Track market-moving stories before they get noisy

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Stryker Corporation (“Stryker” or the “Company”) (NYSE: SYK) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON STRYKER CORPORATION (SYK), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On July 30, 2026, Stryker reported second quarter 2026 results. Among.

BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Stryker Corp. (NYSE: SYK) for potential securities law violations. Investors who have lost money in their Stryker investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/syk.

What is this all about?

Block & Leviton is investigating whether Stryker Corporation and certain of its executives may have violated federal securities laws. On July 30, 2026, Stryker's CEO told investors that the company had "addressed" a manufacturing problem affecting inventory supply in its peripheral vascular business, an issue management indicated it expected to resolve during the third quarter. On September 8, 2026, however, Stryker's CFO disclosed at the Wells Fargo Healthcare Conference that the manufacturing problem remained unresolved and was now expected to persist into the fourth quarter. Stryker shares fell roughly 8% on the news. The investigation concerns whether Stryker misrepresented the status of the manufacturing problem and the health of its business to investors.

Who is eligible?

Anyone who purchased Stryker common stock and has seen their shares fall may be eligible, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more.

What is Block & Leviton doing?

Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money.

What should you do next?

If you've lost money on your investment, you should contact Block & Leviton to learn more via our case website, by email at [email protected], or by phone at (888) 256-2510.

Whistleblower?

If you have non-public information about Stryker, you should consider assisting in our investigation or working with our attorneys to file a report with the Securities Exchange Commission under their whistleblower program. Whistleblowers who provide original information to the SEC may receive rewards of up to 30% of any successful recovery. For more information, contact Block & Leviton at [email protected] or by phone at (888) 256-2510.

Why should you contact Block & Leviton?

Block & Leviton is widely regarded as one of the leading securities class action firms in the country. Our attorneys have recovered billions of dollars for defrauded investors and are dedicated to obtaining significant recoveries on behalf of our clients through active litigation in the federal courts across the country. Many of the nation's top institutional investors hire us to represent their interests. You can learn more about us at our website, www.blockleviton.com, call (888) 256-2510 or email [email protected] with any questions.

This notice may constitute attorney advertising.

CONTACT:
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (888) 256-2510
Email: [email protected]

California State Teachers Retirement System grew its stake in shares of Stryker Corporation (NYSE:SYK – Free Report) by 30,523.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 163,395,348 shares of the medical technology company’s stock after acquiring an additional 162,861,784 shares during the quarter. California State Teachers Retirement System owned about 42.60% of Stryker worth $51,443,391,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of SYK. Rakuten Investment Management Inc. purchased a new position in shares of Stryker in the 2nd quarter worth about $18,646,000. Royal Bank of Canada grew its holdings in shares of Stryker by 6.5% during the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock worth $1,075,552,000 after purchasing an additional 199,863 shares during the period. Crossmark Global Holdings Inc. increased its position in Stryker by 31.1% during the 4th quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock worth $9,426,000 after purchasing an additional 6,367 shares in the last quarter. Rathbones Group PLC increased its position in Stryker by 647.9% during the 4th quarter. Rathbones Group PLC now owns 219,265 shares of the medical technology company’s stock worth $77,065,000 after purchasing an additional 189,948 shares in the last quarter. Finally, Trust Point Inc. raised its holdings in Stryker by 681.9% in the second quarter. Trust Point Inc. now owns 13,480 shares of the medical technology company’s stock valued at $4,244,000 after buying an additional 11,756 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets SYK has been the topic of a number of recent research reports. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Royal Bank Of Canada dropped their price objective on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. Truist Financial lifted their target price on shares of Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a report on Friday, July 31st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Stryker in a research report on Friday, July 31st. Finally, Evercore set a $350.00 price target on Stryker in a report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus price target of $386.28.

Get Our Latest Report on SYK Stryker Price Performance Shares of SYK stock opened at $302.92 on Monday. The firm has a fifty day simple moving average of $328.84 and a 200-day simple moving average of $329.48. The company has a market capitalization of $116.19 billion, a PE ratio of 31.39, a price-to-earnings-growth ratio of 1.90 and a beta of 0.76. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $396.37. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter in the previous year, the firm posted $3.13 EPS. The firm’s quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts anticipate that Stryker Corporation will post 15.03 earnings per share for the current fiscal year.

Stryker Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s payout ratio is presently 36.48%.

Insider Transactions at Stryker In related news, insider Dylan Crotty sold 441 shares of the stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the transaction, the insider owned 6,102 shares of the company’s stock, valued at approximately $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Ronda Stryker sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total value of $17,005,000.00. Following the sale, the director owned 2,251,375 shares of the company’s stock, valued at approximately $765,692,637.50. This trade represents a 2.17% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 351,267 shares of company stock valued at $118,197,701. 4.60% of the stock is currently owned by insiders.

Stryker Profile (Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Featured Articles Five stocks we like better than Stryker AI Token Costs Are Changing the Hardware vs. Software Debate 3 ETFs That Could Move as Rate Expectations Shift 3 Stocks With September Catalysts Investors Shouldn’t Ignore Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Both Intuitive Surgical and Stryker just posted their fifth straight earnings beat, and Wall Street is cheering for both. But a structural difference buried inside their business models quietly separates a compounder from a cyclical recovery story.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Intuitive Surgical (NASDAQ: ISRG | ISRG Price Prediction) and Stryker (NYSE: SYK) both delivered a fifth consecutive EPS beat in Q2 2026. Intuitive rode a fast growing installed base and 36% Ion procedure growth. Stryker fought back from a March cyber incident with 9% organic sales growth. Both raised or narrowed guidance, yet the models diverge in ways that shape long-term returns.

Recurring Revenue Carries Intuitive. Capital Backlog Carries Stryker. Intuitive placed 468 da Vinci systems, including 246 da Vinci 5 units. Instruments and Accessories generated $1.73B, up 18%, and it carries the highest margin in the mix. Non-GAAP gross margin expanded to 70.0%. CEO Dave Rosa said the quarter “reflects the strength of our portfolio”. Recurring revenue reached 85% of the total, a quiet compounding engine most investors underestimate.

Stryker delivered $6.59B in revenue, up 9.4%, with adjusted operating margin expanding 170 bps to 27.4%. MedSurg and Neurotechnology grew 9.7%, and Orthopaedics grew 9.1%. Vascular slipped 0.7% because of an Inari plant supply disruption. CEO Kevin Lobo said the team entered the second half “with regained momentum”.

Business Driver Intuitive Surgical Stryker Q2 Revenue Growth 18.5% 9.4% Recurring Revenue Share 85% Mixed capital and consumables Gross Margin 70.0% 66% AI Deepens One Moat. AI Widens Another’s Reach. Both companies pour resources into artificial intelligence, but the intent differs. Intuitive uses AI to deepen the da Vinci moat. MyIntuitivePlus bundles telepresence, simulation, and AI-driven case insights on da Vinci 5’s platform. Rosa outlined “more than 100 planned updates”. An extended use instrument program arriving in the first half of 2027 should lower cost per procedure and pull more benign cases onto the system, reinforcing the recurring revenue flywheel.

Stryker uses AI to widen its hospital operating system. The new SmartCare unit merges Vocera and Care AI on a modern cloud stack, and management flagged “really big second half of sales growth”. Mako now spans hip, knee, spine, and shoulder across 47 countries, and the handheld Mako RPS is in full US launch. That reflects ecosystem breadth rather than moat depth.

Next Test Cuts Across Robotics and Recovery I will watch the da Vinci 5 upgrade cycle. Management reminded investors that the SI to XI transition took roughly seven years to peak, so trades will trickle through 2027 and beyond. On Stryker’s side, keep an eye on the Inari backorder returning to a manageable level by the end of Q3, plus data from the 1,200-patient Peerless2 trial, which Lobo called “the seminal trial within peripheral vascular”.

Why I Lean Toward Intuitive’s Quiet Compounding I lean toward Intuitive for durable compounding. An installed base of 11,710 da Vinci systems feeds instruments and services every single day, and the AI roadmap keeps sharpening switching costs. Wall Street sees the story too: 25 upward EPS revisions in 30 days for FY2026. Stryker still fits investors who want diversified medtech exposure with a cyber recovery kicker. If Mako RPS conversions accelerate and Inari stabilizes, my view could tilt back toward balance. For now, the quiet advantage sits with Intuitive.

Contact [email protected] for any questions or corrections.

Key Takeaways Stryker agreed to acquire ZuriMED, adding the commercialized FiberLocker System to its shoulder portfolio.The FiberLocker System targets a key clinical failure mode linked to rotator cuff repair.Stryker aims to expand rotator cuff augmentation capabilities across sports medicine and arthroplasty. Stryker (SYK - Free Report) recently announced a definitive agreement to acquire ZuriMED, developer of the FiberLocker System, a commercialized technology designed for rotator cuff augmentation with increased biomechanical strength. The acquisition is aimed at strengthening Stryker’s shoulder portfolio and expanding its ability to support specialists across the continuum of shoulder care.

Per Stryker management, ZuriMED’s technology addresses an important unmet need for shoulder care. The addition of the FiberLocker System is expected to complement Stryker’s existing offerings while reinforcing its focus on advancing innovation and improving patient outcomes.

Likely Trend of SYK Stock Following the NewsFollowing the announcement, SYK shares lost 2.1% at yesterday’s close. Year to date, shares of the company have fallen 7.8% compared with the industry’s 16.3% decline. However, the S&P 500 has risen 11.8% in the same timeframe.

In the long run, the acquisition could support Stryker’s long-term growth by adding a commercialized technology to its existing offerings and potentially increasing its ability to capture demand as rotator cuff procedures expand. The transaction may also create opportunities for deeper relationships with healthcare providers while giving Stryker another avenue to strengthen its position in the competitive sports medicine market.

SYK currently has a market capitalization of $126.84 billion.

Image Source: Zacks Investment Research

More on the NewsZuriMED’s FiberLocker System is a soft tissue augmentation technology designed to address a key clinical failure mode associated with rotator cuff repair. Rotator cuff augmentation is one of the fastest-growing areas within sports medicine and represents a significant opportunity in shoulder care. Through the acquisition, Stryker aims to further strengthen its rotator cuff augmentation capabilities and support shoulder specialists across both sports medicine and arthroplasty.

The transaction remains subject to customary closing conditions. Until the acquisition is completed, Stryker and ZuriMED will continue to operate as separate entities and conduct their businesses as usual.

Industry Prospects Favoring the MarketGoing by the data provided by Grand View Research, the global rotator cuff repair market is estimated to be valued at $994.1 million in 2026 and is expected to witness a CAGR of 7.6% through 2033.

Factors like the rising incidence of degenerative shoulder disorders among the aging population, advancements in arthroscopic repair techniques and growing adoption of orthobiologics to improve surgical outcomes are supporting market growth.

Other NewsIn July, Stryker delivered a strong second quarter, with both earnings and sales beating their respective estimates. The quarterly outperformance reflects a solid recovery from the first-quarter cybersecurity disruption. Broad-based strength across MedSurg, Neurotechnology and Orthopedics, coupled with improving production and healthy hospital capital spending, drove the performance. Management tightened its full-year organic growth outlook, signaling confidence in continued operational recovery, which may get partially offset by a temporary supply disruption within the Inari peripheral vascular business.

SYK’s Zacks Rank & Key PicksStryker currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .

Globus Medical, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Veracyte, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.

VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.

West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

 | Source: Stryker Corporation

Portage, Mich., USA, Aug. 31, 2026 (GLOBE NEWSWIRE) --

Stryker has signed a definitive agreement to acquire ZuriMED, developer of the FiberLocker System, a commercialized technology that provides a novel approach for rotator cuff augmentation designed for increased biomechanical strength.The acquisition strengthens Stryker’s shoulder portfolio, enhancing its ability to support specialists across the continuum of care.The FiberLocker System is a soft tissue augmentation technology designed to reduce the occurrence of a key clinical failure mode in rotator cuff repair, one of the fastest-growing segments in sports medicine.
Stryker (NYSE:SYK), a global leader in medical technologies, announced it has signed a definitive agreement to acquire ZuriMED, a privately held company and developer of the FiberLocker® System. This commercialized technology provides a novel approach for rotator cuff augmentation with increased biomechanical strength to address a key clinical failure mode in rotator cuff repair.

Rotator cuff augmentation is one of the fastest-growing areas in sports medicine and represents a significant opportunity within shoulder care.1 The acquisition will enhance Stryker’s ability to support shoulder specialists across both sports medicine and arthroplasty, strengthening its portfolio in rotator cuff augmentation.

“ZuriMED has developed a differentiated technology that addresses an important clinical need within shoulder care,” said Andy Pierce, Group President, MedSurg and Neurotechnology, Stryker. “We are excited about the opportunity to add the FiberLocker System to Stryker’s portfolio. This acquisition reflects our continued commitment to advancing innovation and improving patient outcomes.”

This transaction is subject to customary closing conditions. Stryker and ZuriMED will continue to operate as separate entities and proceed with business as usual until the transaction closes.

About Stryker        
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

Contacts
For investor inquiries:
Nick Mead
Vice President, Investor Relations
[email protected]

For media inquiries:
Kim Montagnino
Vice President, Chief Communications Officer
[email protected]

References

Mordor Intelligence. Rotator Cuff Treatment Market Size and Share Analysis – Growth, Trends, and Forecasts (2026–2031). Mordor Intelligence report.

 | Source: Stryker Corporation

Portage, Michigan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at the Encore Boston Harbor.

Preston Wells, Vice President, Chief Financial Officer and Nick Mead, Vice President, Investor Relations will also participate in a fireside chat session at 2:15 p.m. (Eastern time). A simultaneous live audio webcast and replay of the session can be accessed at Stryker - Events & Presentations.

About Stryker

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

Contacts

For investor inquiries:
Nick Mead, Vice President, Investor Relations at 269-385-2600 or [email protected]   

For media inquiries:
Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or [email protected]

Beacon Pointe Advisors LLC acquired a new position in Stryker Corporation (NYSE:SYK – Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 40,773 shares of the medical technology company’s stock, valued at approximately $12,838,000.

Several other institutional investors have also recently made changes to their positions in SYK. Sankala Group LLC purchased a new position in shares of Stryker in the fourth quarter valued at $26,000. Godfrey Financial Associates Inc. purchased a new stake in Stryker during the fourth quarter valued at $26,000. United Financial Planning Group LLC bought a new position in Stryker during the third quarter valued at $27,000. Atlas Capital Advisors Inc. bought a new position in Stryker during the fourth quarter valued at $27,000. Finally, Gables Capital Management Inc. purchased a new position in shares of Stryker in the 2nd quarter worth $25,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Price Performance Shares of SYK opened at $331.32 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The company has a 50 day moving average price of $329.10 and a 200-day moving average price of $331.47. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86. The stock has a market capitalization of $127.08 billion, a PE ratio of 34.33, a PEG ratio of 2.05 and a beta of 0.76.

Stryker (NYSE:SYK – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter in the previous year, the firm posted $3.13 earnings per share. Stryker’s revenue for the quarter was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts predict that Stryker Corporation will post 15.02 earnings per share for the current fiscal year. Stryker Announces Dividend The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s payout ratio is currently 36.48%.

Analyst Upgrades and Downgrades Several equities research analysts have recently issued reports on SYK shares. Raymond James Financial set a $370.00 price objective on Stryker in a research note on Friday, July 31st. Citigroup restated a “buy” rating on shares of Stryker in a report on Thursday, August 13th. Canaccord Genuity Group lowered their price target on Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Robert W. Baird set a $385.00 price objective on shares of Stryker in a research report on Friday, May 1st. Finally, Wells Fargo & Company reduced their target price on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $386.28.

View Our Latest Stock Analysis on SYK

Insiders Place Their Bets In other Stryker news, insider Debra King sold 826 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This represents a 11.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Dylan Bram Crotty sold 441 shares of the firm’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the sale, the insider owned 6,102 shares in the company, valued at $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 351,267 shares of company stock worth $118,197,701. 4.60% of the stock is owned by corporate insiders.

Stryker Profile (Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Recommended Stories Five stocks we like better than Stryker 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude? Okta Stock Surges 29%—Is $200 the Next Stop? Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Caisse de depot et placement du Quebec bought a new position in shares of Stryker Corporation (NYSE:SYK – Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 6,529 shares of the medical technology company’s stock, valued at approximately $2,056,000.

Other hedge funds have also modified their holdings of the company. Sankala Group LLC acquired a new position in Stryker during the 4th quarter worth $26,000. Godfrey Financial Associates Inc. acquired a new stake in shares of Stryker in the 4th quarter valued at $26,000. United Financial Planning Group LLC acquired a new stake in shares of Stryker in the 3rd quarter valued at $27,000. Atlas Capital Advisors Inc. bought a new stake in shares of Stryker during the fourth quarter worth $27,000. Finally, Gables Capital Management Inc. bought a new stake in shares of Stryker during the second quarter worth $25,000. 77.09% of the stock is owned by institutional investors.

Insider Activity In related news, insider Debra King sold 826 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider owned 6,210 shares in the company, valued at approximately $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ronda E. Stryker sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the completion of the sale, the director directly owned 2,251,375 shares of the company’s stock, valued at $765,692,637.50. The trade was a 2.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 351,267 shares of company stock valued at $118,197,701 in the last ninety days. 4.60% of the stock is owned by insiders.

Analyst Ratings Changes Several equities analysts recently issued reports on the company. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. JPMorgan Chase & Co. dropped their price objective on Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Citigroup restated a “buy” rating on shares of Stryker in a research report on Thursday, August 13th. BTIG Research reduced their target price on shares of Stryker from $371.00 to $358.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. Finally, Royal Bank Of Canada lowered their price target on shares of Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus target price of $386.28. Get Our Latest Research Report on SYK

Stryker Stock Up 2.9% NYSE:SYK opened at $331.32 on Friday. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $127.08 billion, a P/E ratio of 34.33, a P/E/G ratio of 2.11 and a beta of 0.76. The stock’s fifty day simple moving average is $329.10 and its 200-day simple moving average is $331.47.

Stryker (NYSE:SYK – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts expect that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Dividend Announcement The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s payout ratio is presently 36.48%.

Stryker Company Profile (Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Featured Articles Five stocks we like better than Stryker From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash Venture Into High-Volatility Corners of the Market With These 3 ETFs 3 Retail Stocks to Watch After a Big Consumer Earnings Week

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways SYK delivered 9% organic sales growth in Q2, with strength across MedSurg, Neurotechnology and Orthopaedics.Mako adoption is expanding, with more than 2.5 million procedures and launches in shoulders and RPS.Cybersecurity and supply disruptions remain risks, while temporary tariff benefits complicate margin gains. Stryker (SYK - Free Report) entered 2026 facing an unexpected cyber disruption, yet underlying demand, robotics adoption and international momentum remained strong. While a robust capital pipeline and active acquisition strategy support long-term growth, execution risks tied to recovery efforts, margin pressures and expanding exposure to new markets could shape the company’s performance over the coming quarters.

This Zacks Rank #3 (Hold) company’s shares have lost 6.7% so far this year compared with the industry’s 15.2% decline. The S&P 500 Index has appreciated 11.2% in the same time frame.

Stryker is a global leader in medical technology with a portfolio spanning Orthopaedics, MedSurg and Neurotechnology. The company has a market capitalization of $125.7 billion.

SYK’s bottom line is anticipated to improve 10.4% over the next five years. Its earnings beat estimates in three of the trailing four quarters and missed once, delivering a negative average surprise of 0.73%.

Image Source: Zacks Investment Research

Let’s delve deeper.

Factors Driving SYK’s ProspectsBroad-Based Organic Growth Demonstrates Strong Underlying Demand: Stryker delivered 9% organic sales growth in the second quarter of 2026, with both MedSurg & Neurotechnology and Orthopaedics posting high-single-digit growth. MedSurg & Neurotechnology increased 9.2%, led by strong performances in Instruments, Endoscopy and Medical, while Orthopaedics grew 8.6%. International sales also remained robust at 8.9%, supported by markets including Australia, Germany, Canada, India and Brazil. The breadth of growth is particularly encouraging because it indicates that demand remains resilient across multiple procedure categories rather than being concentrated in a single product franchise. This provides Stryker with a solid foundation for sustaining its 2026 growth outlook.

Mako Robotics Continues to Expand Competitive Advantage: Mako remains a critical growth engine for Stryker, with more than 2.5 million procedures performed globally and systems installed across 47 countries. U.S. knee sales increased 6.2%, supported by continued Mako adoption, while Ortho Tech grew 9.2% on robust Mako installations. The full commercial launch of Mako Shoulder and Mako RPS further expands the platform's addressable procedure base and strengthens Stryker's ability to compete across knees, hips and shoulders. As robotic-assisted surgery gains acceptance, the installed base should create recurring opportunities for implants, instruments and capital equipment, reinforcing Stryker's ecosystem-based competitive moat.

Margin Expansion and Cost Discipline Encouraging: Stryker's second-quarter performance showed meaningful operating leverage, with adjusted EPS rising 17.9% to $3.69. Adjusted gross margin expanded 60 basis points to 66%, and adjusted operating margin increased 170 basis points to 27.4%. Management attributed the improvement to favorable business mix, cost discipline and lower SG&A as a percentage of sales. This is important because the company continues to absorb costs associated with cybersecurity remediation and manufacturing recovery. Stronger margins suggest that Stryker's operational initiatives are offsetting some of these temporary expenses. If revenue momentum persists, incremental sales should increasingly flow through earnings, supporting management's full-year EPS outlook of $14.95-$15.10.

DownsidesCybersecurity Incident Continues to Impact Performance: Although Stryker has largely recovered from its cybersecurity incident, the event continues to weigh on 2026 financial performance. The disruption temporarily shut manufacturing facilities, resulting in lost production absorption and idle costs. Management also expects continued spending on cybersecurity remediation and stabilization throughout the year. The company acknowledged that these costs contribute to a wider EPS guidance range and could limit earnings conversion despite strong revenue growth. While production has been ramped and management believes the recovery is progressing, the episode demonstrates the vulnerability of a highly integrated global manufacturing network. Any additional disruption or slower-than-expected normalization could create further costs, supply constraints and pressure on margins.

Peripheral Vascular Supply Disruptions Are Limiting Near-Term Growth: Stryker's Peripheral Vascular business remains a significant near-term weakness following a supply disruption at a manufacturing facility supporting the Inari portfolio. The issue created a meaningful backlog and resulted in lost sales during the second quarter, offsetting otherwise strong U.S. growth. Management expects backorders to reach manageable levels by the end of the third quarter, but the disruption highlights execution risks within a strategically important growth market. Importantly, management estimated the shortfall was meaningful enough to potentially represent roughly 50-75 basis points of organic growth drag. Until production normalizes, Peripheral Vascular is likely to remain a constraint on consolidated growth despite favorable long-term market fundamentals.

Macro Headwinds Could Pressure Earnings: Stryker's second-quarter margin performance benefited from a net tariff benefit, making the underlying sustainability of margin expansion more complicated. Management noted ongoing pressure from oil and other raw materials while also highlighting continued cybersecurity-related expenses and broader macroeconomic uncertainty. Although the tariff benefit supported second-quarter gross margin, these favorable effects are not necessarily recurring, meaning future quarters could face less favorable comparisons. The company expects strong sales growth to provide earnings leverage, but higher input costs could absorb part of that benefit. Consequently, investors should distinguish between structural productivity gains and temporary cost benefits when assessing the durability of Stryker's 2026 margin trajectory.

Estimate TrendSYK has been witnessing a positive estimate revision trend for 2026. In the past 60 days, the Zacks Consensus Estimate for earnings has increased 3 cents to $15.02 per share.

The consensus mark for third-quarter 2026 revenues is pegged at $6.66 billion, indicating a 10% improvement from the year-ago reported actuals. The bottom-line estimate is pinned at $3.63, implying year-over-year growth of 13.8%.  

Stocks to ConsiderSome better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and The Cooper Companies (COO - Free Report) .

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.

The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.

COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.

AlpenGlobal Capital LLC bought a new stake in Stryker Corporation (NYSE:SYK – Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 6,155 shares of the medical technology company’s stock, valued at approximately $1,938,000. Stryker makes up about 1.2% of AlpenGlobal Capital LLC’s investment portfolio, making the stock its 26th biggest position.

Several other hedge funds have also bought and sold shares of SYK. Norges Bank bought a new position in shares of Stryker in the 4th quarter worth $1,822,272,000. Auto Owners Insurance Co lifted its holdings in shares of Stryker by 35,047.0% during the 4th quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock worth $1,024,444,000 after acquiring an additional 2,906,448 shares during the last quarter. Flossbach Von Storch SE purchased a new position in Stryker in the second quarter worth $464,506,000. Wellington Management Group LLP grew its position in Stryker by 22.6% in the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock worth $2,282,192,000 after acquiring an additional 1,198,665 shares in the last quarter. Finally, Corient Private Wealth LLC increased its stake in Stryker by 104.4% in the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after acquiring an additional 1,146,998 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth Several equities research analysts have issued reports on the company. Raymond James Financial set a $370.00 price target on Stryker in a research note on Friday, July 31st. Sanford C. Bernstein set a $410.00 price objective on Stryker in a research report on Friday, May 1st. BMO Capital Markets began coverage on Stryker in a report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 price objective on the stock. Citizens Jmp dropped their target price on Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research report on Monday, August 3rd. Finally, Robert W. Baird set a $385.00 target price on Stryker in a research note on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus price target of $386.28.

Get Our Latest Stock Analysis on Stryker Insider Activity In related news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Debra King sold 826 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 665,370 shares of company stock valued at $216,238,501. Corporate insiders own 4.60% of the company’s stock.

Stryker Stock Down 3.5% Shares of NYSE:SYK opened at $327.97 on Friday. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The company has a market cap of $125.80 billion, a PE ratio of 33.99, a P/E/G ratio of 2.17 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The stock’s 50-day moving average is $326.64 and its 200 day moving average is $332.66.

Stryker (NYSE:SYK – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm’s revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the firm posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts anticipate that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s payout ratio is presently 36.48%.

About Stryker (Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Featured Stories Five stocks we like better than Stryker 3 Energy Stocks Raising Dividends as the Sector Surges 5 Reasons the S&P 500 Could Keep Rallying Through Year-End Walmart’s Post-Earnings Drop Could Be a Buying Opportunity The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Advisors Preferred LLC acquired a new stake in shares of Stryker Corporation (NYSE:SYK – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 4,300 shares of the medical technology company’s stock, valued at approximately $1,404,000.

A number of other hedge funds have also recently bought and sold shares of SYK. Fairtree Asset Management Pty Ltd acquired a new position in Stryker in the second quarter valued at $2,379,000. Oxford Financial Group LTD. LLC purchased a new position in shares of Stryker in the 2nd quarter worth about $713,000. Kilter Group LLC purchased a new position in shares of Stryker in the 2nd quarter worth about $25,000. D L Carlson Investment Group Inc. acquired a new position in shares of Stryker in the 2nd quarter valued at about $3,089,000. Finally, Portfolio Design Labs LLC purchased a new stake in shares of Stryker during the 2nd quarter worth about $1,348,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Down 3.5% Shares of Stryker stock opened at $327.97 on Friday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The business’s 50 day simple moving average is $326.64 and its 200-day simple moving average is $332.66. The stock has a market capitalization of $125.80 billion, a price-to-earnings ratio of 33.99, a PEG ratio of 2.17 and a beta of 0.76. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $396.86.

Stryker (NYSE:SYK – Get Free Report) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same period in the previous year, the business posted $3.13 EPS. Stryker’s revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current year. Stryker Announces Dividend The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Insider Buying and Selling In other news, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Debra King sold 826 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider directly owned 6,210 shares of the company’s stock, valued at $2,088,423. This represents a 11.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 665,370 shares of company stock valued at $216,238,501 over the last three months. Company insiders own 4.60% of the company’s stock.

Analysts Set New Price Targets Several research firms have recently issued reports on SYK. Piper Sandler dropped their price objective on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Evercore set a $350.00 target price on shares of Stryker in a report on Monday, July 6th. BTIG Research lowered their price target on Stryker from $371.00 to $358.00 and set a “buy” rating for the company in a report on Friday, July 31st. The Goldman Sachs Group reissued a “neutral” rating and issued a $361.00 price objective on shares of Stryker in a research report on Friday, May 1st. Finally, Wolfe Research cut Stryker from an “outperform” rating to a “peer perform” rating in a research note on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $386.28.

Read Our Latest Report on SYK

About Stryker (Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

See Also Five stocks we like better than Stryker 3 Energy Stocks Raising Dividends as the Sector Surges 5 Reasons the S&P 500 Could Keep Rallying Through Year-End Walmart’s Post-Earnings Drop Could Be a Buying Opportunity The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Shares of Stryker Corporation (NYSE:SYK – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the twenty-four research firms that are presently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $386.28.

Several brokerages have issued reports on SYK. Raymond James Financial set a $370.00 target price on Stryker in a report on Friday, July 31st. Robert W. Baird set a $385.00 price target on shares of Stryker in a research report on Friday, May 1st. Piper Sandler cut their price objective on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Truist Financial lifted their target price on shares of Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a research note on Friday, July 31st. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $361.00 price target on shares of Stryker in a research note on Friday, May 1st.

Get Our Latest Analysis on Stryker

Stryker Trading Down 3.5% SYK opened at $327.97 on Friday. The firm has a market capitalization of $125.80 billion, a price-to-earnings ratio of 33.99, a price-to-earnings-growth ratio of 2.17 and a beta of 0.76. The company’s 50 day simple moving average is $326.64 and its two-hundred day simple moving average is $332.66. Stryker has a 1-year low of $281.00 and a 1-year high of $396.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker (NYSE:SYK – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same quarter last year, the firm earned $3.13 earnings per share. The business’s revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Analysts expect that Stryker will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is 36.48%.

Insider Activity In related news, insider Debra King sold 826 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the sale, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. The trade was a 11.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 665,370 shares of company stock valued at $216,238,501 in the last quarter. Insiders own 4.60% of the company’s stock.

Institutional Trading of Stryker Several institutional investors have recently added to or reduced their stakes in SYK. Sankala Group LLC purchased a new position in shares of Stryker during the fourth quarter worth $26,000. Godfrey Financial Associates Inc. purchased a new stake in shares of Stryker in the 4th quarter valued at $26,000. United Financial Planning Group LLC acquired a new position in Stryker during the 3rd quarter worth about $27,000. Atlas Capital Advisors Inc. acquired a new position in Stryker during the 4th quarter worth about $27,000. Finally, Gables Capital Management Inc. purchased a new position in Stryker during the 2nd quarter valued at about $25,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

About Stryker (Get Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Featured Stories Five stocks we like better than Stryker 3 Energy Stocks Raising Dividends as the Sector Surges 5 Reasons the S&P 500 Could Keep Rallying Through Year-End Walmart’s Post-Earnings Drop Could Be a Buying Opportunity The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

BlackRock Inc. cut its position in Stryker Corporation (NYSE:SYK – Free Report) by 0.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,414,742 shares of the medical technology company’s stock after selling 187,307 shares during the quarter. BlackRock Inc. owned about 7.15% of Stryker worth $8,631,257,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of SYK. Varma Mutual Pension Insurance Co raised its position in Stryker by 10.5% during the fourth quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock valued at $18,842,000 after purchasing an additional 5,100 shares in the last quarter. QRG Capital Management Inc. boosted its stake in Stryker by 7.4% in the fourth quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock worth $21,281,000 after buying an additional 4,186 shares in the last quarter. Swedbank AB grew its position in Stryker by 6.6% during the fourth quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock valued at $45,349,000 after acquiring an additional 7,934 shares during the last quarter. Crossmark Global Holdings Inc. boosted its stake in shares of Stryker by 31.1% in the 4th quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock valued at $9,426,000 after purchasing an additional 6,367 shares in the last quarter. Finally, Royal Bank of Canada grew its holdings in shares of Stryker by 6.5% during the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock valued at $1,075,552,000 after purchasing an additional 199,863 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Insider Buying and Selling In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In Several analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft set a $315.00 price target on shares of Stryker in a research note on Friday, May 1st. JPMorgan Chase & Co. decreased their price objective on Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Barclays lowered their target price on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Finally, Truist Financial raised their price target on Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $386.28. Check Out Our Latest Research Report on SYK

Stryker Stock Performance Shares of NYSE:SYK opened at $331.75 on Tuesday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The company has a market cap of $127.25 billion, a price-to-earnings ratio of 34.38, a price-to-earnings-growth ratio of 2.16 and a beta of 0.76. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86. The company has a 50-day moving average price of $325.21 and a 200-day moving average price of $333.24.

Stryker (NYSE:SYK – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts anticipate that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio is currently 36.48%.

Stryker Company Profile (Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

See Also Five stocks we like better than Stryker Commodities Are Booming, But These 3 ETFs Tell Different Stories 3 Active ETFs Making Big Moves in August This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem Birkenstock Beats the Skeptics—But Not on EPS Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Argent Trust Co grew its stake in Stryker Corporation (NYSE: SYK) by 66.4% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,889 shares of the medical technology company's stock after purchasing an additional 6,339 shares during the quarter. Argent

Key Takeaways Stryker shares rose 13.6% in three months as Q2 organic sales grew 9% and adjusted EPS climbed 17.9%.SYK faces production, vascular backlog and cyber-cost pressures as it works to sustain second-half momentum.Stryker trades at 21.6X forward earnings, above the sub-industry's 17.5X but below its five-year median.
Stryker Corporation (SYK - Free Report) shares have risen 13.6% in the past three months, outpacing the Zacks Medical sector’s 12.9% gain and the S&P 500’s 1.7% advance. The move has coincided with a sharper operating recovery after a difficult first quarter.

The investor question is whether improving sales, margins and production can keep supporting the stock, or whether execution demands and a richer relative valuation now make the next leg higher harder to achieve.

Image Source: Zacks Investment Research

Why Stryker’s Three-Month Rally Has SupportStryker’s second-quarter results gave investors firmer operating evidence. Organic sales increased 9%, while adjusted earnings rose 17.9% to $3.69 per share. Management said the company exited the quarter with regained momentum after the March cybersecurity disruption.

Demand remained broad across the portfolio. MedSurg and Neurotechnology organic sales increased 9.2%, while Orthopaedics rose 8.6%. That breadth matters because the recovery is not resting on one product line or a single procedural category.

Stryker’s Q2 Recovery Reset the NarrativeCapital equipment was a major contributor as production came back online, and Stryker ended the quarter with elevated backlog and strong orders. Mako also posted its best-ever second quarter for installations in both the United States and international markets, with utilization continuing to rise.

The competitive backdrop remains active. Zimmer Biomet Holdings, Inc. (ZBH - Free Report) reported 4% organic constant-currency sales growth in its latest quarter and is advancing its ROSA robotic platform. Intuitive Surgical, Inc. (ISRG - Free Report) reported 16% growth in combined da Vinci and Ion procedures and placed 468 da Vinci systems, underscoring continued demand for robotic-assisted care.

SYK Still Faces Execution Tests in the Second HalfThe recovery is not complete. Management still needs to ramp production fast enough to convert a large capital order book, while U.S. Peripheral Vascular back orders are expected to fall to a manageable level by the end of the third quarter.

Costs remain another watch point. Cyber remediation and stabilization spending will continue through the year, while manufacturing and supply-chain costs were roughly a 100-basis-point first-half gross-margin headwind. Those pressures could affect delivery timing and operating leverage if recovery work takes longer than planned.

Valuation Could Cap Stryker’s Next Leg HigherAfter the rally, Stryker trades at 21.6X forward 12-month earnings. That is above the Zacks sub-industry’s 17.5X multiple, suggesting investors are already paying a premium for Stryker’s growth profile and recovery prospects.

The signal is not uniformly expensive, however. SYK remains below its own five-year median of 26X. That leaves valuation in a middle ground: richer than peers, but still below the stock’s longer-term norm.

Image Source: Zacks Investment Research

Wrapping UpStryker’s operating case has improved, but the next phase depends on execution. Production recovery, vascular backlog reduction and continued earnings momentum need to hold up against lingering remediation and manufacturing costs.

Currently, Stryker carries a Zacks Rank #3 (Hold). Likewise, Zimmer Biomet and Intuitive Surgical also carry a Zacks Rank of 2. The investment decision is better anchored to valuation, second-half execution and the durability of earnings growth rather than assuming the recent rally will continue.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Stryker's stronger growth, margin gains and product pipeline support the case, but cyber costs, supply constraints and acquisition execution keep risks elevated.

August 05, 2026 09:34 ET  | Source: Stryker Corporation

Portage, Michigan, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable October 30, 2026, to shareholders of record at the close of business on September 30, 2026, representing an increase of 4.8% versus the prior year and unchanged from the previous quarter. 

About Stryker

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

Contacts

For investor inquiries:
Nick Mead, Vice President, Investor Relations at 269-385-2600 or [email protected]   

For media inquiries:
Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or [email protected]

Key Takeaways Stryker's Q2 EPS rose 17.9% and sales climbed 9.4%, yet shares fell 7.8% after hours.Stryker restored plant operations after the cyber disruption, lifting output and capital order fulfillment.SYK narrowed 2026 guidance as capital backlog, record Mako installs and new launches support the second half. Stryker Corporation (SYK - Free Report) reported second-quarter 2026 adjusted earnings of $3.69 per share, up 17.9% year over year. The figure beat the Zacks Consensus Estimate of $3.46 by 6.6%.

GAAP EPS was $3.30, up 44.1% from the year-ago quarter’s level.

SYK's Sales Growth Regains MomentumRevenues rose 9.4% to $6.59 billion and topped the consensus mark of $6.56 billion by 0.5%. Organic sales advanced 9%, supported by stronger capital deliveries, recovering production and broad demand across the portfolio.

Despite better-than-expected sales and EPS, Stryker tightened its sales and EPS guidance, likely leading to a decline of 7.8% in share price during after-hours trading yesterday. Year to date, the company’s shares have lost 1% compared with the industry’s decline of 16.1%. The S&P 500 Index has increased 6.7% in the same time frame.

Image Source: Zacks Investment Research

The quarter marked a sharp recovery from the cybersecurity disruption that constrained production in the first quarter. Management said plants had returned to consistent operation, allowing Stryker to rebuild output and fulfill more capital orders.

U.S. sales increased 8.9% to $4.96 billion, while international sales climbed 11.0% to $1.63 billion. International growth was led by Australia, New Zealand, Germany, Canada, South Korea, Japan, India and Brazil.

Stryker's MedSurg Portfolio Leads GrowthMedSurg and Neurotechnology sales increased 9.7% to $3.63 billion, with organic growth of 9.2%. Medical was the strongest major business, rising 13.4% to $1.12 billion, aided by demand for preoperative skin-preparation products, powered cots, LIFEPAK 35, ProCuity beds and Smart Care offerings.

Endoscopy sales advanced 11.7% to $1 billion, while Instruments rose 9.3% to $1 billion. Vascular sales declined 0.7% to $496 million because of a supply disruption at an Inari manufacturing site, which created back orders and lost sales.

Management expects Vascular back orders to fall to a manageable level by the end of the third quarter. A stabilized sales force and improving product availability are expected to support a return to growth during the second half.

SYK's Orthopaedics Posts Broad GainsOrthopaedics sales grew 9.1% to $2.96 billion, with organic growth of 8.7%. Trauma and Extremities led the segment with an 11.9% increase to $1.07 billion, reflecting strength in trauma and upper-extremity products.

Ortho Tech sales rose 10.3% to $717 million on robust Mako installations. Knees increased 8.4% to $693 million, while Hips improved 2.9% to $479 million. Management also highlighted record second-quarter Mako installations and rising utilization across the installed base.

The company moved Mako RPS into full commercial launch in the United States. Other product catalysts include Triathlon Gold, the Incompass Total Ankle Replacement System and the planned launch of the SONOPET 3 Ultrasonic Aspirator.

Stryker Expands Margins on Cost DisciplineAdjusted gross profit totaled $4.35 billion in the second quarter, up 10.6% from the year-ago quarter’s level. Adjusted gross margin expanded 60 basis points to 66.0%, aided by favorable tariff effects, business mix and cost discipline.

Research, development and engineering expenses increased 6.6% year over year to $434 million. Selling, general and administrative expenses rose 7.2% to $2.23 billion. Total operating expenses were $2.84 billion, up 4.1% from the prior-year quarter’s level.

Adjusted operating income increased 17.0% to $1.81 billion. Adjusted operating margin improved 170 basis points to 27.4%, reflecting gross margin gains and lower adjusted selling, general and administrative expenses as a percentage of sales.

The margin performance was notable, given continuing cybersecurity remediation expenses, lost manufacturing absorption and raw-material pressures. Management remains committed to its multiyear operating-margin expansion plan.

SYK Strengthens Cash Flow and Capital PlansStryker exited the second quarter with cash and cash equivalents of $3.39 billion compared with $2.88 billion at the end of the first quarter of 2026.

Cumulative net cash provided by operating activities totaled $1.84 billion compared with $1.36 billion a year ago.

Management continues to prioritize acquisitions but plans to resume share repurchases in the third quarter. Stryker has about $1 billion remaining under an existing board authorization, with the timing and scale dependent on deal flow and valuation.

Capital demand remained healthy, with an elevated backlog and no order cancellations reported at quarter-end. Strong orders across Mako, beds and Smart Care provide visibility into second-half deliveries.

Stryker Narrows 2026 OutlookStryker now expects full-year organic sales growth of 8.3-9.3% compared with its earlier guidance of 8.0-9.5%. Adjusted earnings are projected between $14.95 and $15.10 per share versus the prior projection of $14.90 to $15.10.

The outlook assumes a modestly positive pricing contribution and slightly favorable foreign-currency effects if rates remain near current levels. Management expects the second half to benefit from capital backlog conversion, production ramp-up, procedure rescheduling and new product launches.

Our TakeStryker delivered a strong second quarter, with both earnings and sales beating their respective Zacks Consensus Estimate. The quarterly outperformance reflects a solid recovery from the first-quarter cybersecurity disruption. Broad-based strength across MedSurg, Neurotechnology and Orthopaedics, coupled with improving production and healthy hospital capital spending, drove the performance. Management tightened its full-year organic growth outlook, signaling confidence in continued operational recovery, which may get partially offset by a temporary supply disruption within the Inari peripheral vascular business.

Stryker expects this momentum to strengthen through the second half of 2026, supported by an elevated capital equipment backlog, record Mako installations, expanding robotic surgery adoption and a steady cadence of new product launches, including Mako RPS, Triathlon Gold and Pangea. Strategic acquisitions remain a key growth pillar. The integration of Inari expands Stryker's presence in mechanical thrombectomy, while the Amplitude Vascular Systems acquisition broadens its cardiovascular portfolio, reducing reliance on orthopaedics and enhancing long-term diversification.

However, execution risks tied to production ramp-up, the temporary Inari supply disruption, cybersecurity remediation costs and macro pressures such as raw material inflation are likely to persist. Nevertheless, diversified end markets, resilient procedural demand and disciplined capital deployment position Stryker for sustained growth beyond 2026.

SYK's Zacks Rank & Stocks to ConsiderStryker has a Zacks Rank #3 (Hold) at present.

Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , McKesson (MCK - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

West Pharmaceutical reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

West Pharmaceutical has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.

McKesson reported a fourth-quarter fiscal 2026 adjusted EPS of $11.69, which beat the Zacks Consensus Estimate by 1.1%. Revenues of $96.3 billion missed the Zacks Consensus Estimate by 5.5%.

McKesson has an estimated long-term earnings growth rate of 13.7%. MCK’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.1%.

Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.

Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.3%.

Stryker Corporation (SYK) Q2 2026 Earnings Call July 30, 2026 4:30 PM EDT

Company Participants

Kevin Lobo - Chairman & CEO
Nick Mead - Vice President of Investor Relations
Preston Wells - VP & CFO

Conference Call Participants

Joanne Wuensch - Citigroup Inc., Research Division
Robert Marcus - JPMorgan Chase & Co, Research Division
Larry Biegelsen - Wells Fargo Securities, LLC, Research Division
Ryan Zimmerman - BTIG, LLC, Research Division
Travis Steed - BofA Securities, Research Division
Vikramjeet Chopra - BMO Capital Markets Equity Research
Matthew O'Brien - Piper Sandler & Co., Research Division
Vijay Kumar - Evercore ISI Institutional Equities, Research Division
Patrick Wood
Ravi Misra - Truist Securities, Inc., Research Division
Matthew Taylor - Jefferies LLC, Research Division
Mathew Blackman - TD Cowen, Research Division
Caitlin Roberts - Canaccord Genuity Corp., Research Division

Presentation

Operator

Welcome to the Second Quarter 2026 Stryker Earnings Call. My name is Megan, and I'll be your operator for today's call. [Operator Instructions]. This conference call is being recorded for replay purposes.

Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC. Also, the discussions will include certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release that is an exhibit to Stryker's current report on Form 8-K filed with the SEC.

I will now turn the call over to Mr. Kevin Lobo, Chair and Chief Executive Officer. You may proceed, sir.

Kevin Lobo
Chairman & CEO

Welcome to Stryker's second quarter earnings call. Joining me today are Preston Wells, Stryker's CFO; and Nick Mead, Vice President of Investor Relations. For today's call, I will provide opening comments, followed by Nick with market trends and some product updates. Preston will then provide additional

Stryker (SYK - Free Report) came out with quarterly earnings of $3.69 per share, beating the Zacks Consensus Estimate of $3.46 per share. This compares to earnings of $3.13 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +6.65%. A quarter ago, it was expected that this medical device maker would post earnings of $2.98 per share when it actually produced earnings of $2.6, delivering a surprise of -12.75%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Stryker, which belongs to the Zacks Medical - Products industry, posted revenues of $6.59 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 0.48%. This compares to year-ago revenues of $6.02 billion. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Stryker shares have added about 0.2% since the beginning of the year versus the S&P 500's gain of 6.9%.

What's Next for Stryker?While Stryker has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Stryker was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $3.73 on $6.72 billion in revenues for the coming quarter and $14.99 on $27.22 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 34% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Agilent Technologies (A - Free Report) , another stock in the same industry, has yet to report results for the quarter ended July 2026. The results are expected to be released on August 26.

This scientific instrument maker is expected to post quarterly earnings of $1.48 per share in its upcoming report, which represents a year-over-year change of +8%. The consensus EPS estimate for the quarter has been revised 0.3% higher over the last 30 days to the current level.

Agilent Technologies' revenues are expected to be $1.84 billion, up 6% from the year-ago quarter.

Portage, Michigan, July 30, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2026:

Second Quarter Results

Reported net sales increased 9.4% to $6.6 billionOrganic net sales increased 9.0%Reported operating income margin of 25.2%Adjusted operating income margin(1) increased 170 bps to 27.4%Reported EPS increased 44.1% to $3.30Adjusted EPS(1) increased 17.9% to $3.69  Second Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology        9.7        %         0.5        %         9.2        %         —        %         9.2        %Orthopaedics        9.1                  0.4                  8.7                  0.1                  8.6         Total        9.4        %         0.4        %         9.0        %         —        %         9.0        % “We made significant progress in our recovery from the cyber incident, delivering strong growth in sales, earnings per share and operating cash flow in the second quarter,” said Kevin A. Lobo, Chair and CEO. “As we have seen in the past, the resilience of our teams when faced with challenges was once again on display. With our steady cadence of innovation and disciplined operational execution, we enter the second half of 2026 with regained momentum and remain confident in our ability to grow at the high end of MedTech.”

Sales Analysis

Consolidated net sales of $6.6 billion increased 9.4% in the quarter and 9.0% in constant currency. Organic net sales increased 9.0% in the quarter from increased unit volume.

MedSurg and Neurotechnology net sales of $3.6 billion increased 9.7% in the quarter and 9.2% in constant currency. Organic net sales increased 9.2% in the quarter including 9.1% from increased unit volume and 0.1% from higher prices.

Orthopaedics net sales of $3.0 billion increased 9.1% in the quarter and 8.7% in constant currency. Organic net sales increased 8.6% in the quarter from increased unit volume.

Earnings Analysis

Reported net earnings of $1.3 billion increased 44.3% in the quarter. Reported net earnings per diluted share of $3.30 increased 44.1% in the quarter. Reported gross profit margin and reported operating income margin were 68.3% and 25.2% in the quarter. Reported net earnings include certain items, such as charges for acquisition and integration-related activities, the amortization of purchased intangible assets, structural optimization and other special charges, goodwill and other impairments, costs to comply with certain medical device regulations, recall-related matters, regulatory and legal matters and tax matters. Excluding the aforementioned items, adjusted gross profit margin(1) was 66.0% in the quarter, and adjusted operating income margin(1) was 27.4% in the quarter. Adjusted net earnings(1) of $1.4 billion increased 17.6% in the quarter. Adjusted net earnings per diluted share(1) of $3.69 increased 17.9% in the quarter.

2026 Outlook

We are narrowing our full year 2026 guidance and now expect organic net sales growth(2) in the range of 8.3% to 9.3% and adjusted net earnings per diluted share(2) in the range of $14.95 to $15.10. Our sales guidance includes a modestly positive pricing impact. Additionally, foreign exchange is expected to have a slightly favorable impact on both sales and adjusted net earnings per diluted share(2) should rates hold near current levels.

(1) A reconciliation of the non-GAAP financial measures: adjusted gross profit margin, adjusted operating income and adjusted operating income margin, adjusted net earnings and adjusted net earnings per diluted share, to the most directly comparable GAAP measures: gross profit margin, operating income and operating income margin, net earnings and net earnings per diluted share, and other important information accompanies this press release.

(2) We are unable to present a quantitative reconciliation of our expected net sales growth to expected organic net sales growth as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of acquisitions and divestitures and the impact of foreign currency exchange rates. We are unable to present a quantitative reconciliation of our expected net earnings per diluted share to expected adjusted net earnings per diluted share as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of structural optimization and other special charges, acquisition-related expenses and the outcome of certain regulatory, legal and tax matters. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our Consolidated Statements of Earnings.

Conference Call on Thursday, July 30, 2026

As previously announced, we will host a conference call on Thursday, July 30, 2026 at 4:30 p.m., Eastern Time, to discuss our operating results for the quarter ended June 30, 2026 and provide an operational update.

Please register for this conference call at: https://stryker-2q2026-earnings.open-exchange.net. After registering, a confirmation will be sent via email, including dial-in details and unique conference call access codes required for call entry. Registration is open throughout the live call. To ensure you are connected prior to the beginning of the call, we suggest registering a minimum of 15 minutes before the start of the call.

A simultaneous webcast of the call will be accessible via the Investor Relations page of our website at www.stryker.com. For those not planning to ask a question of management, we recommend listening via the webcast. Please allow 15 minutes to register, download and install any necessary software.

Following the conference call, a replay will be available on our website up to one year from the time of the earnings call.

Caution Concerning Forward-Looking Statements

This press release contains information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such risks and uncertainties include, but are not limited to: weakening of economic conditions, or the anticipation thereof, that could adversely affect the level of demand for our products; geopolitical risks, including from tariffs and the potential for further changes in trade policies and international conflicts, which have led to and could continue to lead to, among other things, increased market volatility; pricing pressures generally, including cost-containment measures that have adversely affected and could in the future adversely affect the price of or demand for our products; changes in foreign currency exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect approval of new products by the United States Food and Drug Administration and foreign regulatory agencies; inflationary pressures; increased interest rates or interest rate volatility; supply chain disruptions; changes in labor markets; changes in coverage and reimbursement levels from third-party payors; changes in the competitive environment; breaches, failures or other disruptions of our or our vendors’ or customers’ information technology systems or products resulting from cyber-attack, data leakage, unauthorized access or theft, including the cybersecurity incident first reported on March 11, 2026; a significant increase in product liability claims; the ultimate total cost with respect to recall-related and other regulatory and quality matters; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; changes in tax laws and regulations; the impact of legislation to reform the healthcare system in the United States or other countries; costs to comply with medical device regulations; changes in financial markets; changes in our credit ratings; our ability to integrate and realize the anticipated benefits of acquisitions in full or at all or within the expected timeframes; our ability to realize any anticipated cost savings; risks relating to climate change or other environmental, social and governance and sustainability related matters; and the impact on our operations and financial results of any public health emergency and any related policies and actions by governments or other third parties. Additional information concerning these and other factors is contained in our filings with the United States Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that affect the likelihood that actual results will differ from those contained in the forward-looking statements, except to the extent required by law.

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

For investor inquiries:

Nick Mead, Vice President, Investor Relations at 269-385-2600 or [email protected]

For media inquiries:
Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or [email protected]

STRYKER CORPORATIONFor the Three and Six Months June 30(Unaudited - Millions of Dollars, Except Per Share Amounts)            CONSOLIDATED STATEMENTS OF EARNINGS         Three Months Six Months  2026   2025  % Change  2026   2025  % ChangeNet sales$        6,589          $        6,022                  9.4        % $        12,609          $        11,888                  6.1        %Cost of sales         2,091                   2,181                  (4.1)                  4,301                   4,303                  —         Gross profit$        4,498          $        3,841                  17.1        % $        8,308          $        7,585                  9.5        %% of sales         68.3        %          63.8        %            65.9        %          63.8        %  Research, development and engineering expenses         434                   407                  6.6                   847                   812                  4.3         Selling, general and administrative expenses         2,229                   2,079                  7.2                   4,510                   4,379                  3.0         Amortization of intangible assets         175                   187                  (6.4)                  355                   354                  0.3         Goodwill and other impairments         1                   55          nm          1                   90          nmTotal operating expenses$        2,839          $        2,728                  4.1        % $        5,713          $        5,635                  1.4        %Operating income$        1,659          $        1,113                  49.1        % $        2,595          $        1,950                  33.1        %% of sales         25.2        %          18.5        %            20.6        %          16.4        %  Other income (expense), net         (95)                  (97)                 (2.1)        %          (181)                  (170)                 6.5         Earnings before income taxes$        1,564          $        1,016                  53.9        % $        2,414          $        1,780                  35.6        %Income taxes         288                   132                  118.2                   393                   242                  62.4         Net earnings$        1,276          $        884                  44.3        % $        2,021          $        1,538                  31.4        %Net earnings per share of common stock:           Basic$        3.32          $        2.32                  43.1        % $        5.27          $        4.03                  30.8        %Diluted$        3.30          $        2.29                  44.1        % $        5.23          $        3.98                  31.4        %Weighted-average shares outstanding (in millions):           Basic 383.5   382.2     383.2   382.0   Diluted 386.0   386.4     386.2   386.4    CONDENSED CONSOLIDATED BALANCE SHEETS                  June 30        December 31   2026                       2025                       Assets   Cash and cash equivalents$        3,391         $        4,011        Marketable securities         85                  89        Accounts receivable, net         3,743                  4,039        Inventories         5,521                  5,310        Prepaid expenses and other current assets         1,678                  1,306        Total current assets$        14,418         $        14,755        Property, plant and equipment, net         3,958                  3,876        Goodwill and other intangibles, net         25,326                  24,972        Noncurrent deferred income tax assets         994                  1,098        Other noncurrent assets         3,234                  3,143        Total assets$        47,930         $        47,844        Liabilities and shareholders' equity   Current liabilities$        6,684         $        7,794        Long-term debt, excluding current maturities         14,192                  14,859        Income taxes         406                  402        Other noncurrent liabilities         2,660                  2,369        Shareholders' equity         23,988                  22,420        Total liabilities and shareholders' equity$        47,930         $        47,844         CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Six Months  2026           2025         Operating activities   Net earnings$        2,021          $        1,538         Depreciation         241                   214         Amortization of intangible assets         355                   354         Changes in operating assets, liabilities, income taxes payable and other, net         (775)                  (745)        Net cash provided by operating activities$        1,842          $        1,361         Investing activities   Acquisitions, net of cash acquired$        (459)         $        (4,814)        Proceeds/(Purchases) of short-term investments         —                   750         Purchases of property, plant and equipment         (368)                  (306)        Other investing, net         3                   130         Net cash used in investing activities$        (824)         $        (4,240)        Financing activities   Borrowings (payments) of debt, net$        (750)         $        2,331         Payments of dividends         (674)                  (641)        Other financing, net         (181)                  (145)        Net cash provided by (used in) financing activities$        (1,605)         $        1,545         Effect of exchange rate changes on cash and cash equivalents         (33)                  57         Change in cash and cash equivalents$        (620)         $        (1,277)         STRYKER CORPORATIONFor the Three and Six Months June 30(Unaudited - Millions of Dollars) SALES GROWTH ANALYSIS Three Months Six Months     Percentage Change     Percentage Change  2026  2025 As ReportedConstant Currency  2026  2025 As ReportedConstant CurrencyMedSurg and Neurotechnology:             Instruments             United States$        840         $        776                 8.4        %        8.4        % $        1,606         $        1,478                 8.7        %        8.7        %International         163                  142                 13.9                 12.3                   317                  278                 13.9                 9.6         Total$        1,003         $        918                 9.3        %        9.0        % $        1,923         $        1,756                 9.6        %        8.9        %Endoscopy             United States$        819         $        742                 10.2        %        10.2        % $        1,520         $        1,452                 4.6        %        4.6        %International         185                  157                 18.8                 16.5                   352                  314                 12.4                 8.1         Total$        1,004         $        899                 11.7        %        11.3        % $        1,872         $        1,766                 6.0        %        5.3        %Medical             United States$        945         $        840                 12.6        %        12.6        % $        1,692         $        1,642                 3.1        %        3.1        %International         177                  150                 17.9                 15.0                   332                  293                 13.2                 8.1         Total$        1,122         $        990                 13.4        %        13.0        % $        2,024         $        1,935                 4.6        %        3.9        %Vascular             United States$        250         $        268                 (6.7)        %        (6.7)        % $        530         $        471                 12.5        %        12.5        %International         246                  230                 6.3                 4.0                   483                  433                 11.3                 7.1         Total$        496         $        498                 (0.7)        %        (1.8)        % $        1,013         $        904                 11.9        %        9.9        %MedSurg and Neurotechnology             United States$        2,854         $        2,626                 8.7        %        8.7        % $        5,348         $        5,043                 6.1        %        6.1        %International         771                  679                 13.3                 11.1                   1,484                  1,318                 12.5                 8.1         Total$        3,625         $        3,305                 9.7        %        9.2        % $        6,832         $        6,361                 7.4        %        6.5        %              Orthopaedics:             Knees             United States$        488         $        460                 6.2        %        6.2        % $        960         $        924                 3.8        %        3.8        %International         205                  180                 14.0                 12.4                   403                  355                 13.7                 9.2         Total$        693         $        640                 8.4        %        8.0        % $        1,363         $        1,279                 6.6        %        5.3        %Hips             United States$        296         $        283                 4.9        %        4.9        % $        572         $        552                 3.6        %        3.6        %International         183                  183                 —                 (0.8)                  367                  357                 2.9                 (0.6)        Total$        479         $        466                 2.9        %        2.6        % $        939         $        909                 3.3        %        1.9        %Trauma and Extremities             United States$        791         $        702                 12.5        %        12.5        % $        1,558         $        1,415                 10.1        %        10.1        %International         281                  255                 10.3                 8.5                   549                  487                 12.7                 7.7         Total$        1,072         $        957                 11.9        %        11.5        % $        2,107         $        1,902                 10.7        %        9.4        %Ortho Tech             United States$        530         $        483                 9.5        %        9.5        % $        997         $        942                 5.8        %        5.8        %International         187                  166                 12.8                 11.8                   366                  324                 12.9                 9.2         Total$        717         $        649                 10.3        %        10.0        % $        1,363         $        1,266                 7.6        %        6.7        % $        2,961         $        2,712                 9.2        %        8.8        % $        5,772         $        5,356                 7.7        %        6.5        %Spinal Implants             United States$        —         $        —                 (100.0)        %        (100.0)        % $        —         $        118                 (100.0)        %        (100.0)        %International         3                  5                 (36.7)                (40.9)                  5                  53                 (90.2)                (91.2)        Total$        3         $        5                 (36.7)        %        (40.9)        % $        5         $        171                 (96.9)        %        (97.1)        %Orthopaedics             United States$        2,105         $        1,928                 9.1        %        9.1        % $        4,087         $        3,951                 3.4        %        3.4        %International         859                  789                 8.9                 7.6                   1,690                  1,576                 7.2                 3.0         Total$        2,964         $        2,717                 9.1        %        8.7        % $        5,777         $        5,527                 4.5        %        3.3        %              Geographic:             United States$        4,959         $        4,554                 8.9        %        8.9        % $        9,435         $        8,994                 4.9        %        4.9        %International         1,630                  1,468                 11.0                 9.2                   3,174                  2,894                 9.7                 5.3         Total$        6,589         $        6,022                 9.4        %        9.0        % $        12,609         $        11,888                 6.1        %        5.0        % Note: In the first quarter 2026 we announced a change in our organizational structure. Our new Ortho Tech business combines the orthopaedic instruments portfolio (Orthopaedic Instruments) from Instruments with Other Orthopaedics. In addition, Neuro Cranial and the spine enabling technologies portfolio (Enabling Technologies) from Other Orthopaedics were combined with the remaining Instruments business to align with our internal reporting structure. Ortho Tech includes sales related to Orthopaedic Instruments of $523 and $501 and Other Orthopaedics of $194 and $148 for the three months 2026 and 2025. For the six months 2026 and 2025 Ortho Tech includes sales related to Orthopaedic Instruments of $1,012 and $985 and Other Orthopaedics of $351 and $281. Instruments includes sales related to Neuro Cranial of $681 and $616 and Enabling Technologies of $28 and $34 for the three months 2026 and 2025. For the six months 2026 and 2025 Instruments includes sales related to Neuro Cranial of $1,287 and $1,179 and Enabling Technologies of $54 and $63. We have reflected these changes in all historical periods presented.

SUPPLEMENTAL INFORMATION - RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

We supplement the reporting of our financial information determined under accounting principles generally accepted in the United States (GAAP) with certain non-GAAP financial measures, including: percentage sales growth in constant currency; percentage organic sales growth; adjusted gross profit; adjusted selling, general and administrative expenses; adjusted research, development and engineering expenses; adjusted operating income; adjusted other income (expense), net; adjusted income taxes; adjusted effective income tax rate; adjusted net earnings; and adjusted net earnings per diluted share (Diluted EPS). We believe these non-GAAP financial measures provide meaningful information to assist investors and shareholders in understanding our financial results and assessing our prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of our operations because they exclude items that may not be indicative of or are unrelated to our core operating results and provide a baseline for analyzing trends in our underlying businesses. Management uses these non-GAAP financial measures for reviewing the operating results of reportable business segments and analyzing potential future business trends in connection with our budget process and bases certain management incentive compensation on these non-GAAP financial measures.

To measure percentage sales growth in constant currency, we remove the impact of changes in foreign currency exchange rates that affect the comparability and trend of sales. Percentage sales growth in constant currency is calculated by translating current and prior year results at the same foreign currency exchange rate. To measure percentage organic sales growth, we remove the impact of changes in foreign currency exchange rates, acquisitions and divestitures, which affect the comparability and trend of sales. Percentage organic sales growth is calculated by translating current year and prior year results at the same foreign currency exchange rates excluding the impact of acquisitions and divestitures. To measure earnings performance on a consistent and comparable basis, we exclude certain items that affect the comparability of operating results and the trend of earnings. The income tax effect of each adjustment was determined based on the tax effect of the jurisdiction in which the related pre-tax adjustment was recorded. These adjustments are irregular in timing and may not be indicative of our past and future performance.

Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, selling, general and administrative expenses, research, development and engineering expenses, operating income, other income (expense), net, income taxes, effective income tax rate, net earnings and net earnings per diluted share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of our operations that, when viewed with our GAAP results and the reconciliations to corresponding GAAP financial measures below, provide a more complete understanding of our business. We strongly encourage investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.

The following reconciles the non-GAAP financial measures discussed above with the most directly comparable GAAP financial measures. The weighted-average diluted shares outstanding used in the calculation of adjusted net earnings per diluted share are the same as those used in the calculation of reported net earnings per diluted share for the respective period.

STRYKER CORPORATIONFor the Three and Six Months June 30(Unaudited - Millions of Dollars, Except Per Share Amounts)          Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial MeasuresThree Months 2026Gross ProfitSelling, General & Administrative ExpensesResearch, Development & Engineering ExpensesOperating IncomeOther Income (Expense), NetIncome TaxesNet EarningsEffective
Tax RateDiluted EPSReported$        4,498         $        2,229         $        434         $        1,659         $     (95)          $        288         $        1,276                 18.4        %$        3.30         Reported percent net sales         68.3        %         33.8        %         6.6        %         25.2        %        (1.4)        %nm         19.4        %  Acquisition and integration-related costs:         Inventory stepped-up to fair value         —                  —                  —                  —                  —                  —                  —                 —                  —         Other acquisition and integration-related (a)         7                  (14)                 (4)                 25                  —                  3                  22                 —                  0.06         Amortization of purchased intangible assets         —                  —                  —                  175                  —                  33                  142                 0.3                  0.37         Structural optimization and other special charges (b)         5                  (89)                 (1)                 95                  (6)                 20                  69                 0.3                  0.18         Goodwill and other impairments (c)         —                  —                  —                  1                  —                  —                  1                 —                  —         Medical device regulations (d)         —                  —                  (5)                 5                  —                  1                  4                 —                  0.01         Recall-related matters (e)         (1)                  (3)                 —                  2                  —                  1                  1                 —                  —         Regulatory and legal matters (f)         —                  (3)                 —                  3                  —                  —                  3                 —                  —         Tax matters (g)         —                  —                  —                  —                  —                  (39)                 39                (2.5)                  0.11         Reversal of 2025 tariffs         (158)                 —                  —                  (158)                 —                  (25)                 (133)               —               (0.34)        Adjusted$        4,351         $        2,120         $        424         $        1,807         $      (101)       $        282         $        1,424                 16.5        %$        3.69         Adjusted percent net sales         66.0        %         32.2        %         6.4        %         27.4        %        (1.5)        %nm         21.6        %   Three Months 2025Gross ProfitSelling, General & Administrative ExpensesResearch, Development & Engineering ExpensesOperating IncomeOther Income (Expense), NetIncome TaxesNet EarningsEffective
Tax RateDiluted EPSReported$        3,841         $        2,079         $        407         $        1,113         $        (97)         $        132         $        884                 13.0        %$        2.29        Reported percent net sales         63.8        %         34.5        %         6.8        %         18.5        %        (1.6)        %nm         14.7        %  Acquisition and integration-related costs:         Inventory stepped-up to fair value         65                  —                  —                  65                  —                  16                  49                 0.5                  0.12        Other acquisition and integration-related (a)         1                  (76)                  (1)                 78                  —                  20                  58                 0.7                  0.15        Amortization of purchased intangible assets         —                  —                  —                  187                  —                  39                  148                 1.0                  0.37        Structural optimization and other special charges (b)         6                  (2)                  (3)                  11                  (9)                  (2)                 4              (0.2)                  0.01        Goodwill and other impairments (c)         —                  —                  —                  55                  —                  22                  33                 1.2                  0.10        Medical device regulations (d)         —                  —                  (7)                  7                  —                  1                  6                 0.1                  0.02        Recall-related matters (e)         21                  (1)                  —                  22                  —                  1                  21               (0.3)                 0.06        Regulatory and legal matters (f)         —                  (7)                  —                  7                  —                  1                  6                 0.1                  0.01        Tax matters (g)         —                  —                  —                  —                  —                  (2)                 2               (0.2)                 —        Adjusted$        3,934         $        1,993         $        396         $        1,545         $        (106)       $        228         $        1,211                 15.9        %$        3.13        Adjusted percent net sales         65.4        %         33.1        %         6.6        %         25.7        %        (1.8)        %nm         20.1        %   nm - not meaningful

(a) Charges represent certain acquisition and integration-related costs associated with acquisitions, including:

 Three Months  2026           2025        Termination of sales relationships$        6          $        —        Employee retention and workforce reductions         (3)                  29        Changes in the fair value of contingent consideration         6                   3        Manufacturing integration costs         5                   3        Other integration-related activities (e.g., deal costs and legal entity rationalization)         11                   43        Adjustments to Operating Income $        25          $        78        Adjustments to Income Taxes$        3          $        20        Adjustments to Net Earnings$        22          $        58         (b) Structural optimization and other special charges represent the costs associated with:

 Three Months  2026           2025         Employee retention and workforce reductions$        6          $        5         Closure/transfer of manufacturing and other facilities (e.g., site closure, contract termination and redundant employee costs)         4                   7         Product line exits         9                   (10)        Termination of sales relationships in certain countries         6                   (3)        Other charges         70                   12         Adjustments to Operating Income $        95          $        11         Adjustments to Other Income (Expense), Net$        (6)         $        (9)        Adjustments to Income Taxes$        20          $        (2)        Adjustments to Net Earnings$        69          $        4          (c) Goodwill and other impairments represent the costs associated with:

 Three Months  2026         2025       Certain long-lived and intangible asset write-offs and impairments$        —         $        52        Product line exits (e.g., long-lived asset and specifically-identified intangible asset write-offs)         1                  3        Adjustments to Operating Income$        1         $        55        Adjustments to Income Taxes$        —         $        22        Adjustments to Net Earnings$        1         $        33         (d) Charges represent the costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the new medical device regulations in the European Union.
(e) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to resolve certain recall-related matters.
(f) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to resolve certain regulatory or other legal matters and the amount of favorable awards from settlements.
(g) Benefits / (charges) represent the accounting impact of certain significant and discrete tax items, including:

 Three Months  2026    2025 Adjustments related to the transfer of certain intellectual properties between tax jurisdictions$        (55)  $        (45)  Other tax matters 16    43   Adjustments to Income Taxes$        (39)  $        (2)  Adjustments to Other Income (Expense), Net$        —   $        —  Adjustments to Net Earnings$        39   $        2    Six Months 2026Gross ProfitSelling, General & Administrative ExpensesResearch, Development & Engineering ExpensesOperating IncomeOther Income (Expense), NetIncome TaxesNet EarningsEffective
Tax RateDiluted EPSReported$        8,308         $        4,510         $        847         $        2,595         $        (181)         $        393         $        2,021                 16.3        %$        5.23         Reported percent net sales         65.9        %         35.8        %         6.7        %         20.6        %        (1.4)        %nm         16.0        %  Acquisition and integration-related costs:         Inventory stepped-up to fair value         —                  —                  —                  —                  —                  —                  —                 —                  —         Other acquisition and integration-related (a)         9                  (27)                 (8)                 44                  —                  7                  37                 —                  0.10         Amortization of purchased intangible assets         —                  —                  —                  355                  —                  63                  292                 0.3                  0.75         Structural optimization and other special charges (b)         19                  (193)                 (1)                 213                  (17)                 45                  151                 0.6                  0.39         Goodwill and other impairments (c)         —                  —                  —                  1                  —                  —                  1                 —                  —         Medical device regulations (d)         —                  —                (10)                  10                  —                  2                  8                 —                  0.02         Recall-related matters (e)         —                  (12)                 —                  12                  —                  3                  9                 —                  0.02         Regulatory and legal matters (f)         —                  (6)                 —                  6                  —                  1                  5                 —                  0.01         Tax matters (g)         —                  —                  —                  —                  —                  (37)                 37               (1.5)                  0.11         Reversal of 2025 tariffs         (158)                 —                  —                  (158)                 —                  (25)                 (133)                —                (0.34)        Adjusted$        8,178         $        4,272         $        828         $        3,078         $        (198)        $        452         $        2,428                 15.7        %$        6.29         Adjusted percent net sales         64.9        %         33.9        %         6.6        %         24.4        %        (1.6)        %nm         19.3        %   Six Months 2025Gross ProfitSelling, General & Administrative ExpensesResearch, Development & Engineering ExpensesOperating IncomeOther Income (Expense), NetIncome TaxesNet EarningsEffective
Tax RateDiluted EPSReported$        7,585         $        4,379         $        812         $        1,950         $     (170)          $        242         $        1,538                 13.6        %$        3.98        Reported percent net sales         63.8        %         36.8        %         6.8        %         16.4        %        (1.4)        %nm         12.9        %  Acquisition and integration-related costs:         Inventory stepped-up to fair value         99                  —                  —                  99                  —                  24                  75                 0.5                  0.19        Other acquisition and integration-related (a)         14                  (247)                 (2)                 263                  —                  26                  237              (0.7)                  0.62        Amortization of purchased intangible assets         —                  —                  —                  354                  —                  73                  281                 1.1                  0.72        Structural optimization and other special charges (b)         28                  (21)                 (3)                 52                  (9)                 12                  31                 0.3                  0.08        Goodwill and other impairments (c)         —                  —                  —                  90                  —                  31                  59                 1.0                  0.16        Medical device regulations (d)         1                  —               (18)                 19                  —                  4                  15                 0.1                  0.04        Recall-related matters (e)         52                  (3)                 —                  55                  —                  9                  46                 0.1                  0.12        Regulatory and legal matters (f)         —                  (7)                 —                  7                  —                  2                  5                 0.1                  0.01        Tax matters (g)         —                  —                  —                  —                  —                  (21)                 21              (1.2)                 0.05        Adjusted$        7,779         $        4,101         $        789         $        2,889         $       (179)       $        402         $        2,308                 14.9        %$        5.97        Adjusted percent net sales         65.4        %         34.5        %         6.6        %         24.3        %        (1.5)        %nm         19.4        %   (a) Charges represent certain acquisition and integration-related costs associated with acquisitions, including:

 Six Months  2026          2025        Termination of sales relationships$        6         $        —        Employee retention and workforce reductions         —                  45        Changes in the fair value of contingent consideration         9                  1        Manufacturing integration costs         10                  7        Stock compensation payments upon a change in control         —                  139        Other integration-related activities (e.g., deal costs and legal entity rationalization)         19                  71        Adjustments to Operating Income $        44         $        263        Adjustments to Income Taxes$        7         $        26        Adjustments to Net Earnings$        37         $        237         (b) Structural optimization and other special charges represent the costs associated with:

 Six Months  2026           2025         Employee retention and workforce reductions$        13          $        38         Closure/transfer of manufacturing and other facilities (e.g., site closure, contract termination and redundant employee costs)         9                   12         Product line exits (e.g., inventory, long-lived asset and specifically-identified intangible asset write-offs)         11                   (7)        Termination of sales relationships in certain countries         87                   (4)        Other charges         93                   13         Adjustments to Operating Income $        213          $        52         Adjustments to Other Income (Expense), Net$        (17)         $        (9)        Adjustments to Income Taxes$        45          $        12         Adjustments to Net Earnings$        151          $        31          (c) Goodwill and other impairments represent the costs associated with:

 Six Months  2026         2025        Certain long-lived and intangible asset write-offs and impairments$        —         $        86        Product line exits (e.g., long-lived asset and specifically-identified intangible asset write-offs)         1                  4        Adjustments to Operating Income$        1         $        90        Adjustments to Income Taxes$        —         $        31        Adjustments to Net Earnings$        1         $        59         (d) Charges represent the costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the new medical device regulations in the European Union.
(e) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to resolve certain recall-related matters.
(f) Charges represent changes in our best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within a range is not known, to resolve certain regulatory or other legal matters and the amount of favorable awards from settlements.
(g) Benefits / (charges) represent the accounting impact of certain significant and discrete tax items, including:

 Six Months  2026    2025  Adjustments related to the transfer of certain intellectual properties between tax jurisdictions$        (75)   $        (92)  Other tax matters 38     71   Adjustments to Income Taxes$        (37)   $        (21)  Adjustments to Other Income (Expense), Net$        —    $        —   Adjustments to Net Earnings$        37    $        21   

Medical product makers face Q2 margin pressure from tariffs and inflation even as demand stays strong. See which earnings reports could surprise.

Key Takeaways Stryker's Q2 is expected to benefit from deferred revenue recovery after the prior cyber disruption.SYK is seeing strong Mako adoption, healthy procedure volumes and continued orthopaedics momentum.Stryker expects pricing, manufacturing gains and revenue recovery to help offset cost pressures. Stryker Corporation (SYK - Free Report) is scheduled to release second-quarter 2026 results on July 30, after market close. In the last reported quarter, the company delivered a negative earnings surprise of 12.57%.

Q2 EstimatesThe Zacks Consensus Estimate for earnings is pegged at $3.46 per share, indicating an increase of 10.5% year over year.

The consensus mark for revenues is pinned at $6.56 billion, implying growth of 8.9% from the prior-year reported figure.

Factors to NoteStryker is expected to report another quarter of healthy underlying performance, supported by resilient procedural demand, continued robotic surgery adoption and strong capital equipment orders. While the company’s first-quarter results were significantly disrupted by a cyber incident that delayed shipments and revenue recognition, management emphasized that underlying market demand remained healthy and reaffirmed full-year organic sales growth guidance of 8-9.5%.

The upcoming quarterly results are likely to reflect the initial recovery from deferred first-quarter revenues, particularly from revenue recognition catch-up in Orthopaedics, while additional recovery from delayed capital equipment shipments is also expected to continue through the second half of the year.

Within the Orthopaedics segment, growth is likely to have been supported by robust procedural volumes, continued market share gains and sustained momentum for the Mako robotic platform. The company delivered a record first quarter for Mako installations despite the cyber disruption, with utilization rates continuing to improve globally.

New product launches, including Mako 4, Mako Shoulder, Mako RPS and Triathlon Gold, are expected to have supported customer interest, while the recently formed Ortho Tech business should have improved commercial execution by combining Mako, enabling technologies and orthopaedic instruments under one organization. Trauma is also likely to have benefited from continued adoption of the Pangea plating system, with European approvals providing an additional growth opportunity.

The MedSurg and Neurotechnology segment is expected to have experienced a more gradual recovery, as capital-intensive businesses such as Medical and Endoscopy were more heavily affected by production shutdowns during the cyber incident. Management indicated that delayed manufacturing of made-to-order products, including beds and other capital equipment, would primarily recover during the second half of the year. Nevertheless, underlying hospital capital spending remains healthy, with an elevated order backlog supporting demand. Continued adoption of LIFEPAK 35, Smart Hospital solutions integrating Vocera and care.ai, and upcoming launches such as Sonopet 4 should provide additional growth support.

Meanwhile, margins are expected to improve sequentially as production normalizes, although tariff-related costs and higher input prices may continue to weigh on gross margin. First-quarter profitability was pressured by lower manufacturing absorption, tariffs and higher interest expense following the Inari acquisition.

However, management maintained its full-year adjusted EPS guidance of $14.90-$15.10, reflecting confidence that deferred revenue recovery, continued pricing discipline, manufacturing efficiencies and operational excellence initiatives will offset near-term cost headwinds as the year progresses.

What the Zacks Model UnveilsOur proven model does not conclusively predict an earnings beat for Stryker this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.

Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is 0.00% for SYK. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.

Zacks Rank: The company carries a Zacks Rank #3 at present.

SYK’s Share Price PerformanceSo far this year, Stryker’s shares have lost 6% compared with the industry’s 20.4% decline. The S&P 500 has gained 7.5% during the said period.

Image Source: Zacks Investment Research

Stocks Worth a LookHere are some stocks worth considering from the broader medical sector, as these have the right combination of elements to post an earnings beat this reporting cycle.

Cardinal Health (CAH - Free Report) has an Earnings ESP of +1.24% and a Zacks Rank #2 at present. The company is set to release fourth-quarter fiscal 2026 results on Aug. 11. You can see the complete list of today’s Zacks #1 Rankstocks here.

CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%. The Zacks Consensus Estimate for CAH’s fourth-quarter EPS indicates an improvement of 16.4% from the year-ago reported figure.

Henry Schein (HSIC - Free Report) has an Earnings ESP of +0.41% and a Zacks Rank #3 (Hold) at present. The company is scheduled to release second-quarter 2026 results on Aug. 4.

HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 3.74%. The Zacks Consensus Estimate for HSIC’s second-quarter EPS implies an improvement of 10.9% from the year-ago reported figure.

Agilent Technologies (A - Free Report) has an Earnings ESP of +1.02% and a Zacks Rank of 3 at present.

A’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 1.61%. The Zacks Consensus Estimate for A’s third-quarter fiscal 2026 EPS calls for an improvement of 8% from the year-ago reported figure.

Posted by Defense World Staff on Jul 22nd, 2026

Dimensional Fund Advisors LP decreased its position in shares of Stryker Corporation (NYSE:SYK – Free Report) by 1.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,242,500 shares of the medical technology company’s stock after selling 18,151 shares during the period. Dimensional Fund Advisors LP owned 0.32% of Stryker worth $408,258,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Godfrey Financial Associates Inc. purchased a new position in Stryker in the fourth quarter worth $26,000. Sankala Group LLC purchased a new position in shares of Stryker during the 4th quarter worth about $26,000. United Financial Planning Group LLC purchased a new position in shares of Stryker in the 3rd quarter worth $27,000. Atlas Capital Advisors Inc. acquired a new position in Stryker during the fourth quarter valued at approximately $27,000. Finally, DJE Kapital AG acquired a new position in shares of Stryker during the fourth quarter worth about $28,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the business’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 5,220 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the sale, the vice president directly owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. This represents a 28.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets Several research analysts recently commented on SYK shares. JPMorgan Chase & Co. cut their price target on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Canaccord Genuity Group decreased their price target on Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Evercore set a $350.00 target price on Stryker in a report on Monday, July 6th. Citigroup reduced their price objective on shares of Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. Finally, Weiss Ratings lowered shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and a consensus price target of $392.52.

Read Our Latest Stock Analysis on Stryker

Stryker Price Performance Shares of NYSE:SYK opened at $313.89 on Wednesday. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The company has a market cap of $120.33 billion, a price-to-earnings ratio of 36.33, a PEG ratio of 2.04 and a beta of 0.77. The business has a 50 day moving average price of $313.79 and a 200 day moving average price of $336.20. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $404.87.

Stryker (NYSE:SYK – Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Research analysts predict that Stryker Corporation will post 14.99 earnings per share for the current year.

Stryker Dividend Announcement The company also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Stryker Company Profile (Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Further Reading Five stocks we like better than Stryker Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEToll Brothers Inc. $TOL Shares Bought by Dimensional Fund Advisors LP

NEXT HEADLINE »California Public Employees Retirement System Boosts Stake in Nordson Corporation $NDSN